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Asia boasts the main economic players of the 21st century.China, India and Japan especially will play main roles in
the field of science, particularly in applied modern technolo-
gies. The concept of socio-genetic marginalization, which is
central to SMAP, draws attention to the consequences of the
practice of relating the social to the (assumed) genetic make-
up of people, regardless of the relevance of such connections.
Central are the socio-cultural and financial consequences of
the use of genetic information. The projects of SMAP are con-
ceptualised through three empirical research projects outlined
below.
Genomics, population-policies and local
traditions 
Governments in China, India, Japan and Europe treat issues
of population planning with various levels of importance and
apply different political strategies. In China the issue of the
new eugenics, the quality of the population and one-child birth
policy are of great political and human significance. The one-
child policy, widely practised since the late-1970s, in combi-
nation with a preference for males, has led to a lopsided
growth of the population. By legal prohibition the state has
tried to interfere against these practices, but as yet not suc-
cessfully. In India, too, sterilisation, infanticide and prenatal
gender discrimination followed by abortion have led to a pop-
ulation imbalance, in which the state tries to interfere. Japan
and Europe, on the other hand, struggle with the problem of
ageing population and falling levels of fertility. 
Thus, a variety of genetic technologies are available to the state
in policies aimed at raising the quality of the population. Such
population policies are part of an attempt to ‘improve’ the
genetic composition of individuals or entire peoples. The 1995
introduction of the new eugenic legislation in China, for
example, supports the systematic ‘implementation of pre-
marital medical check-ups’ on hereditary, venereal or repro-
ductive disorders as well as mental disorders so as to prevent
‘inferior births’ (Ministry of Public Health, 1994) A different
tendency can be found in the Netherlands, where members
of the medical profession observe that the state is obstructing
their duty of providing all possible information and alterna-
tive treatment to patients by not allowing them to practice pre-
embryo-screening and prenatal genetic research 
There is a need for the comparison of clashes of state popula-
tion policies with local traditions in India, China, and Japan.
Modern technologies of genetic engineering increasingly allow
the government to intervene and regulate the personal lives
of individuals in the name of public health, religion and
national good. Concomitantly, concepts of health and human
values in society are likely to be influenced. However, in some
cultural environments, such as in India, it is the state that tries
to put a brake onto the prenatal gender selection of its popu-
lation. 
Genetic sampling and vulnerable groupings
in genetic sampling sites 
The twofold aims of this project are, first, to understand the
socioeconomic and cultural conditions of genetic sampling
and banking in isolated areas and among ethnic minorities in
different national contexts and, second, to the ways in which
research populations are defined and mapped by researchers.
The DNA of these socially defined groups is the subject of
research in evolutionary genetics, the study of human reac-
tions to various pharmaceutical products (pharmacogenetics),
and the study of single nucleotide polymorphism (SNPs).1 Two
kinds of issues are central to this research. The first involves
the bioethical aspects of sampling and storing DNA. Current
bioethical protocols still fail to deal adequately with the spe-
cific conditions raised by population-based research, in par-
ticular regarding procedures for group decision-making and
cultural divergence (MST & MPH 1998; ICMR 2000). The
second involves problems inherent in the ways geneticists
define sample populations in genetic research. Before the sam-
pling of populations begins, estimates are made about the
genetic nature of target populations. The contents of these
estimates are intimately related to historical processes of eth-
nic group formation, the intricacies of cultural perception and
political interests. 
In India, China and Taiwan, the DNA of various minority
groups with suspect unique DNA are exploited commercial-
ly by research groups abroad and at home. This has caused
considerable local, national and international strain. In Yun-
nan in Southwest China, ethnic DNA of over 25 so-called
national minorities is stored in the world’s largest ethnic data-
bank in Kunming (People’s Daily, 22/11/00). Such research is
used to support claims on ethnic and national identity and to
resolve conflict over national territory. Bio-anthropological
research from South India served to provide genetic evidence
for the similarity between high caste Indians and Europeans
(Bamshad 2001). In Japan and China similar population
research attempts to ‘scientifically’ root the modern nation
into venerable historical origins.
Genomics, sociogenetic identities and health
strategies in China, India and Japan
Though increased genetic information means a step forward
in predicting and curing genetic diseases, policy-makers also
attempt to use it strategically to improve human populations
and eliminate ‘defective’ phenotypes. In the private sphere
parallel developments are taking place: early prenatal testing
has motivated couples with an increased risk of affected off-
spring to have children, but the diagnosis of disorders has also
led to a steep increase of selective abortion. A central question
here is if and when we can speak of a link between national
health care policy, public debate and the private sphere. For
instance, in China the government started a one-child fami-
ly-planning programme in the 1970s to ensure sufficient
nutrition for all new-borns, which resulted in a substantially
decreased birth rate. At the same time, this policy limits indi-
vidual freedom and autonomy. On the other hand, infant mor-
tality in China by the 1990s had become considerably lower
than in India. The criteria for the cost-effectiveness of clinical
genetics in developing countries are not the same as in wealthy
countries, such as Japan, Singapore and Taiwan. In develop-
ing countries the severely handicapped do not usually survive
and, if they do, they are not provided with expensive medical
care. Consequently, the targets of genetics services are reached
on the basis of a different balance sheet. Thus, in developing
countries family planning, carrier testing, genetic counselling
and prenatal diagnosis may have a different rationale. 
Currently six researchers are working on SMAP. Focusing on
reproductive genetic technologies (RGT’s) and genetic coun-
selling in Delhi and Mumbai in India, Dr Jyotsna Gupta stud-
ies how genetic screening affects the perception of genetic
risk. To understand these processes, Gupta conducts fieldwork
in hospital locations of diverging religious and socio-economic
status. In her analysis, Gupta uses the categories of gender,
religion, education and socio-economic status to understand
the parental decisions made to abort or to carry the embryo to
full term. At the same time, she relates her observations in
these clinics to state-regulation, developments in the phar-
maceutical industry and international bioethical guidelines
and NGOs.
The application of RGTs in Japan and its effect on genetic
selection after prenatal diagnosis and during pre-implanta-
tion genetic diagnosis (PGD) are central in the work of Dr
Masae Kato. Her fieldwork focuses on the way parents make
decisions about their offspring in genetic counselling sessions,
and the way government guidelines, medical institutions, the
family and cultural-medical practices affect these decisions.
Kato relates her findings to political and public debates on the
socio-cultural value of the embryo, so as to understand process-
es of validating humans. Initially, Kato will compare the appli-
cation of RGTs in Japan with those in the Netherlands, extend-
ing the comparison to the PRC next.
Interested in genetic sampling, screening and biobanking in
India, Prasanna Patra studies medical policies on three tribes
with high levels of sickle cell anaemia, whose socio-econom-
ic circumstances differ starkly, and investigates how screen-
ing affects the identity and health of the community. In gen-
eral, Patra looks at what happens to genetic data and asks the
following questions: who does the sampling and under what
conditions? Where are the data stored and who has access to
them? Patra aims to make sense of the various behaviours and
motives of various interest groups, including academic
researchers, pharmaceutical companies, state agencies, sam-
pled communities and NGOs.
Two research students will start to work with us in September
2005. Suli Sui will conduct comparative research into the reg-
ulation of new genetic technologies regarding vulnerable pop-
ulations. She reviews existing Chinese law in relation to gen-
der, ethnic, and socio-economic status, after which she will
compare similar issues in the context of regulation of
genomics and society in India. Apart from weighing argu-
ments in favour and against the universal regulation of
biotechnology, she will offer recommendations on regulation
that harm the interests of identified vulnerable populations. 
The second research student, Jan-Eerik Leppanen, aims to
understand the role of Chinese ethnic minorities in biobank-
ing and hopes to gain a better understanding of the effects of
the knowledge generated through genetic sampling. Apart
from exploring how biobanking activities alter relations
between ethnic groups and the state, and what commercial
stakes are involved, this research tries to understand the social
and cultural effects of these activities on the ethnic groups in
question. <
Note
1 Single nucleotide polymorphisms or SNPs (pronounced ‘snips’)
are DNA sequence variations that occur when a single nucleotide
(A,T,C,or G) in the genome sequence is altered.
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Margaret Sleeboom-Faulkner (University of Amsterdam), who leads
the programme, conducts research mainly in the areas of biobanking,
stem cell research and genetic counselling in China and Japan. 
SMAP, the Socio-genetic Marginalization in Asia Programme, which started off in August 2004, is a research programme set up with
the support of the Netherlands Science Organisation (NWO), IIAS, and the Amsterdam School for Social Science Research (ASSR).
Exploring cultural, social and economic aspects of the role of genetic technologies played in the area of state organisation,
population policies, health care systems and research regulation in China, India and Japan, SMAP is expected to shed light on how
differences in the application of modern genetic technologies generate different practices. The programme focuses on: (I) the ways
in which (universal) regulation for genetic sampling by international companies and universities leads to disputable research
practices among vulnerable populations; (II) how bioethical differences between healthcare systems are expressed in the different
meanings allocated to concepts, such as informed consent, health, and family values; and, (III) the consequences of development
priorities and practices of genetic screening for the livelihood and identities of diverging social groups.
